JP7741100B2 - ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 - Google Patents

ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Info

Publication number
JP7741100B2
JP7741100B2 JP2022567488A JP2022567488A JP7741100B2 JP 7741100 B2 JP7741100 B2 JP 7741100B2 JP 2022567488 A JP2022567488 A JP 2022567488A JP 2022567488 A JP2022567488 A JP 2022567488A JP 7741100 B2 JP7741100 B2 JP 7741100B2
Authority
JP
Japan
Prior art keywords
pyrimidin
chloro
fluorophenyl
morpholinyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524806A5 (https=
JP2023524806A (ja
Inventor
チャバニウク，ララ・シー
ホッパー，ティモシー
ハウズ，ジョナサン・ビー
レスクリオ，グウェンアエラ
サントラ，ビンセント
ワン，ハオシュエン
ホワイト，ライアン・ディー
ウォン，アリス・アール
ウー，ヨンウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2023524806A publication Critical patent/JP2023524806A/ja
Publication of JP2023524806A5 publication Critical patent/JP2023524806A5/ja
Priority to JP2025146675A priority Critical patent/JP2025179173A/ja
Application granted granted Critical
Publication of JP7741100B2 publication Critical patent/JP7741100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2022567488A 2020-05-04 2021-05-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 Active JP7741100B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025146675A JP2025179173A (ja) 2020-05-04 2025-09-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019768P 2020-05-04 2020-05-04
US63/019,768 2020-05-04
PCT/US2021/030719 WO2021226135A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025146675A Division JP2025179173A (ja) 2020-05-04 2025-09-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2023524806A JP2023524806A (ja) 2023-06-13
JP2023524806A5 JP2023524806A5 (https=) 2024-05-17
JP7741100B2 true JP7741100B2 (ja) 2025-09-17

Family

ID=78468393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567488A Active JP7741100B2 (ja) 2020-05-04 2021-05-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
JP2025146675A Pending JP2025179173A (ja) 2020-05-04 2025-09-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025146675A Pending JP2025179173A (ja) 2020-05-04 2025-09-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Country Status (19)

Country Link
US (4) US12252489B2 (https=)
EP (1) EP4146220B1 (https=)
JP (2) JP7741100B2 (https=)
KR (1) KR20230020983A (https=)
CN (1) CN116322696A (https=)
AU (1) AU2021267161A1 (https=)
BR (1) BR112022022338A2 (https=)
CA (1) CA3182541A1 (https=)
CL (1) CL2022003041A1 (https=)
CO (1) CO2022015927A2 (https=)
CR (1) CR20220559A (https=)
CU (1) CU20220065A7 (https=)
EC (1) ECSP22089520A (https=)
IL (2) IL325121A (https=)
JO (1) JOP20220295A1 (https=)
MX (1) MX2022013838A (https=)
PE (1) PE20230609A1 (https=)
PH (1) PH12022552933A1 (https=)
WO (1) WO2021226135A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
JP7741100B2 (ja) 2020-05-04 2025-09-17 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
WO2023086800A1 (en) * 2021-11-09 2023-05-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso
EP4430022A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS USED AS AGONISTS OF THE TRIGGER RECEPTOR EXPRESSED ON MYELOID CELLS 2 AND METHODS OF USE
WO2024008722A2 (en) * 2022-07-04 2024-01-11 Muna Therapeutics Aps Trem2 modulators
TW202517639A (zh) 2023-07-17 2025-05-01 丹麥商穆納醫療有限責任公司 Trem2調節劑
WO2025136898A1 (en) * 2023-12-18 2025-06-26 Merck Sharp & Dohme Llc Agonists of trem2 activity
TW202535410A (zh) 2024-01-04 2025-09-16 丹麥商穆納醫療有限責任公司 Ｔｒｅｍ２調節劑
WO2025146477A1 (en) 2024-01-04 2025-07-10 Muna Therapeutics Aps 2-azetidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives derivatives as trem2 modulators for the treatment of neurodegenerative diseases
WO2025176753A1 (en) * 2024-02-22 2025-08-28 F. Hoffmann-La Roche Ag Condensed pyrimidine derivates als trem2 agonists
WO2025176748A1 (en) * 2024-02-22 2025-08-28 F. Hoffmann-La Roche Ag Condensed pyrazines or pyrimidines als trem2 agoonists
WO2025191114A1 (en) * 2024-03-14 2025-09-18 Muna Therapeutics Aps Trem2 modulators
WO2026077861A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists
WO2026077862A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511779A (ja) 2008-02-01 2011-04-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としてのピリド［４，３−ｄ］ピリミドン誘導体
WO2014051653A1 (en) 2012-09-27 2014-04-03 Portola Pharmaceuticals, Inc. Bicyclic dihydropyridone kinase inhibitors
US20140342924A1 (en) 2011-06-02 2014-11-20 Almac Diagnostics Limited Molecular Diagnostic Test for Cancer
JP2023525035A (ja) 2020-05-04 2023-06-14 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
US3712892A (en) 1969-08-02 1973-01-23 Sumitomo Chemical Co Quinazolinone derivatives
JPH05170744A (ja) 1991-12-25 1993-07-09 Toray Dow Corning Silicone Co Ltd 含窒素芳香族複素環式化合物のアルキル化方法
EP0743855A1 (en) 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
DK1028950T3 (da) 1997-10-28 2003-09-01 Warner Lambert Co 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
JP2004521892A (ja) 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
JP4690043B2 (ja) 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
GB0229281D0 (en) 2002-12-16 2003-01-22 Novartis Ag Organic compounds
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
PL1673092T3 (pl) 2003-10-17 2008-01-31 4 Aza Ip Nv Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu
JP2007510642A (ja) 2003-11-03 2007-04-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬
RU2358969C2 (ru) 2004-02-13 2009-06-20 Баниу Фармасьютикал Ко., Лтд. Конденсированное 4-оксопиримидиновое производное
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
NZ551004A (en) 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
KR100659088B1 (ko) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
JP2009509963A (ja) 2005-09-23 2009-03-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
JP2009528387A (ja) 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
WO2008003149A2 (en) 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
CA2659851C (en) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
MX2010004074A (es) 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010042925A2 (en) 2008-10-10 2010-04-15 Vm Discovery Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8722692B2 (en) * 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
WO2011014039A1 (en) 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
US20110124597A1 (en) 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
BR112012022868A2 (pt) 2010-03-16 2018-06-05 Merck Patent Gmbh morfolinilquinazolinas
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
KR101497124B1 (ko) 2011-11-28 2015-03-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치
SG11201404743TA (en) 2012-02-08 2014-09-26 Janssen R & D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
CN103374021B (zh) 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014146249A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
WO2015002729A2 (en) * 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
ES2750236T3 (es) 2013-12-09 2020-03-25 UCB Biopharma SRL Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
KR20150080966A (ko) 2014-01-02 2015-07-13 최돈수 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
KR20160060572A (ko) 2014-11-19 2016-05-30 주식회사 엠비케이 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기
RU2717665C2 (ru) 2015-04-15 2020-03-24 Ф. Хоффманн-Ля Рош Аг Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата
US10403826B2 (en) 2015-05-07 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
EP3335254B1 (de) 2015-08-11 2020-04-08 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
US10573692B2 (en) 2016-04-06 2020-02-25 Samsung Display Co., Ltd. Organic light-emitting device having a sealing thin film encapsulation portion
PL3442947T3 (pl) 2016-04-15 2023-10-02 Epizyme, Inc. Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
US11283028B2 (en) 2016-10-05 2022-03-22 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
CN109790183A (zh) 2016-12-13 2019-05-21 广州华睿光电材料有限公司 金属有机配合物及其应用、混合物、有机电子器件
TW201843143A (zh) 2017-03-13 2018-12-16 德商麥克專利有限公司 含有芳基胺結構之化合物
WO2018169352A1 (en) 2017-03-16 2018-09-20 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
KR102335935B1 (ko) 2017-03-22 2021-12-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US20200113901A1 (en) 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
KR102389204B1 (ko) 2017-04-18 2022-04-21 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
WO2018204764A1 (en) * 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
CN110996945A (zh) 2017-06-13 2020-04-10 联邦科学技术研究组织 抗病毒药物
EP3689866A4 (en) 2017-09-26 2021-07-07 Nippon Soda Co., Ltd. QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE
AU2018353139A1 (en) 2017-10-18 2020-06-04 Epizyme, Inc. Methods of using EHMT2 inhibitors in immunotherapies
JP2021500326A (ja) 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
CN108484680B (zh) 2018-01-31 2020-12-11 马鞍山南京大学高新技术研究院 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
CN109265457A (zh) 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
WO2020231739A2 (en) 2019-05-10 2020-11-19 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
CN110283171A (zh) 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用
US11820783B2 (en) 2019-09-06 2023-11-21 Universal Display Corporation Organic electroluminescent materials and devices
BR112022022184A2 (pt) 2020-05-04 2023-01-17 Takeda Pharmaceuticals Co Derivados de n-(piperidin-4-il)benzamida agindo luminalmente
JP7741100B2 (ja) 2020-05-04 2025-09-17 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
IL297864A (en) 2020-05-04 2023-01-01 Adama Makhteshim Ltd Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof
CN111454265B (zh) 2020-05-07 2021-08-24 宁波卢米蓝新材料有限公司 一种稠杂环化合物及其制备方法和应用
CA3244298A1 (en) 2022-01-11 2023-07-20 Regeneron Pharmaceuticals, Inc. TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL VARIANTS 2 (TREM2) AND ITS USES IN THE TREATMENT OF ALZHEIMER'S DISEASE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511779A (ja) 2008-02-01 2011-04-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としてのピリド［４，３−ｄ］ピリミドン誘導体
US20140342924A1 (en) 2011-06-02 2014-11-20 Almac Diagnostics Limited Molecular Diagnostic Test for Cancer
WO2014051653A1 (en) 2012-09-27 2014-04-03 Portola Pharmaceuticals, Inc. Bicyclic dihydropyridone kinase inhibitors
JP2023525035A (ja) 2020-05-04 2023-06-14 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Also Published As

Publication number Publication date
MX2022013838A (es) 2023-02-22
PE20230609A1 (es) 2023-04-13
PH12022552933A1 (en) 2024-02-12
US12319691B2 (en) 2025-06-03
CN116322696A (zh) 2023-06-23
AU2021267161A1 (en) 2022-12-08
US20230144581A1 (en) 2023-05-11
CO2022015927A2 (es) 2023-01-26
JOP20220295A1 (ar) 2022-11-02
CA3182541A1 (en) 2021-11-11
CL2022003041A1 (es) 2023-07-14
ECSP22089520A (es) 2023-02-28
EP4146220B1 (en) 2026-02-18
KR20230020983A (ko) 2023-02-13
US20240190863A1 (en) 2024-06-13
IL297845A (en) 2023-01-01
BR112022022338A2 (pt) 2023-01-10
US20240124446A1 (en) 2024-04-18
JP2025179173A (ja) 2025-12-09
CU20220065A7 (es) 2023-06-13
IL297845B1 (en) 2026-01-01
US12252489B2 (en) 2025-03-18
JP2023524806A (ja) 2023-06-13
US11718617B2 (en) 2023-08-08
WO2021226135A1 (en) 2021-11-11
EP4146220A4 (en) 2024-05-29
IL325121A (en) 2026-02-01
EP4146220A1 (en) 2023-03-15
CR20220559A (es) 2023-08-18
EP4146220C0 (en) 2026-02-18
US20250388574A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
JP7741100B2 (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
JP7754846B2 (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法
JP5433418B2 (ja) 多環式化合物
KR101601571B1 (ko) 2-아미노-4-(피리딘-2-일)-5,6-디히드로-4h-1,3-옥사진 유도체 및 bace-1 및/또는 bace-2 억제제로서의 그의 용도
KR102234131B1 (ko) 피리디닐피라졸로퀴놀린 화합물
TW202309029A (zh) 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2023086800A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
JP2014532066A (ja) オキサジン誘導体および神経障害の処置におけるその使用
JP2024545591A (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
WO2023086799A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists
WO2024233848A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2024233847A2 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2025128873A1 (en) Heterocyclic pyridinone compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
KR20220118483A (ko) Oga 억제제 화합물
TW202535410A (zh) Ｔｒｅｍ２調節劑
EA052247B1 (ru) Гетероциклические соединения в качестве агонистов триггерного рецептора 2 миелоидных клеток и способы их применения
HK40096431A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
WO2025146476A1 (en) 2-(tetrahydro-2h-pyran-4-yl)-7-methyl-8-oxo-6-(trifluoromethyl)-7,8-dihydropyrimido[5,4-d]pyrimidine derivatives as trem2 modulators for the treatment of neurodegenerative diseases
WO2017090716A1 (ja) ピラゾール誘導体の結晶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250904

R150 Certificate of patent or registration of utility model

Ref document number: 7741100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150